Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.43 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751803 | 0.90 | MEN1 (0.38) | BACE1PSMB5KDM4EALDH1A1BACE2 | |
| SCHEMBL5752618 | 0.88 | HPGDS (0.37) | BACE1PSMB5KDM4EALDH1A1BACE2 | |
| SCHEMBL5753023 | 0.88 | BACE1 (0.35) | BACE1CTSDPSMB5KDM4EALDH1A1 | |
| SCHEMBL5752370 | 0.88 | BACE1 (0.41) | BACE1PSMB5KDM4EALDH1A1BACE2 | |
| SCHEMBL7122508 | 0.87 | ALDH1A1 (0.41) | BACE1PSMB5KDM4EALDH1A1BACE2 | |
| SCHEMBL5751588 | 0.86 | BACE1 (0.37) | BACE1CTSDBCHEPSMB5BACE2 | |
| SCHEMBL5751020 | 0.86 | MDM2 (0.43) | BACE1CTSDBCHEBACE2 | |
| SCHEMBL5752714 | 0.85 | PPARG (0.39) | BACE1 | |
| SCHEMBL5755540 | 0.83 | MAPK14 (0.41) | BACE1CTSD | |
| SCHEMBL5749273 | 0.83 | BACE1 (0.37) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | BACE1 835/4885CTSD 4290/4885BCHE 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.